CRNX vs SION
CRNX: Crinetics Pharmaceuticals is a clinical-stage biotechnology company developing small molecule precision medicines for rare endocrine diseases and related tumors. SION: A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
Side-by-side fundamentals
| Metric | CRNX | SION | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $83.86 | $49.94 | |
| Market cap as of 2026-08-05 | $8.8B | $2.3B | |
| PEG as of 2026-08-05 | -0.73 | -0.89 | SION lower |
| Net margin as of 2026-08-05 | -2747.2% | n/a | |
| Gross margin as of 2026-08-05 | +86.0% | n/a | |
| Operating margin as of 2026-08-05 | -3020.3% | n/a | |
| ROE as of 2026-08-05 | -44.0% | -27.3% | SION higher |
| ROA as of 2026-08-05 | -39.6% | -25.9% | SION higher |
| Debt / equity as of 2026-08-05 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-05 | +2277.5% | n/a | |
| Beta as of 2026-08-05 | 0.02 | 0.92 | |
| 1-year return as of 2026-08-04 close | +197.2% | +191.7% | CRNX higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.